The Study to YD312 Tablet in Patients With Diabetic Macular Edema

Phase 2 Unknown 100 enrolled YD Global Life Science Co., Ltd.

RandomizedParallel-groupTriple-blindTreatment

Summary

This study objectives is to evaluate the efficacy of YD312 to improve visual acuity in patients with diabetic macular edema (DME) compared to placebo and determine optimal dose of phase 2b study.

Timeline

Start: 2017-10-19
Primary completion: 2018-07-27
Completion: 2020-03-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	YD312	Unknown	50 mg	—
Subject	YD312	Unknown	150 mg	—
Subject	YD312	Unknown	350 mg	—

The Study to YD312 Tablet in Patients With Diabetic Macular Edema

Summary

Timeline

Drugs

Indications